Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL-22 binding protein

Molecular Carcinogenesis

Volumn 54, Issue 10, 2015, Pages 986-998

  Janakiram, Naveena B ^a   Mohammed, Altaf ^a   Bryant, Taylor ^a   Brewer, Misty ^a   Biddick, Laura ^a   Lightfoot, Stan ^a   Lang, Mark L ^a   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

ApcMin + mice; Colorectal cancer; NK cells; Rag 1 mice; Tregs

Indexed keywords

APC PROTEIN; BINDING PROTEIN; GAMMA INTERFERON; INTERLEUKIN 22; PURINERGIC P2X7 RECEPTOR; RAG1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-22; INTERLEUKIN-22 RECEPTOR; STAT3 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER SIZE; CARCINOGENESIS; CELL SURVIVAL; COLON TUMOR; COLORECTAL CANCER; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; INTESTINE POLYP; INTESTINE TUMOR; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SPLEEN CELL; WEIGHT GAIN; ANIMAL; C57BL MOUSE; IMMUNOLOGY; INFLAMMATION; INTESTINE; PATHOLOGY; PROCEDURES;

ADOPTIVE TRANSFER; ANIMALS; CARCINOGENESIS; FEMALE; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKINS; INTESTINES; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, INTERLEUKIN; RECEPTORS, PURINERGIC P2X7; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 84941618385     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22168     Document Type: Article

References (30)

1. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-510.
2. Coca S, Perez-Piqueras J, Martinez D, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79:2320-2328.
3. Halama N, Braun M, Kahlert C, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 2011; 17:678-689.
4. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88:577-583.
5. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: How do they suppress immune responses? Int Immunol 2009; 21:1105-1111.
6. Ward ST, Hepburn E, Li K, et al. Selective recruitment and retainment of regulatory T cells in human colorectal cancer. Lancet 2013; 381:S113.
7. Blatner NR, Mulcahy MF, Dennis KL, et al. Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med 2012; 4:164ra159.
8. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+ CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 2003; 98:1089-1099.
9. Min/+ mice. Cancer Res 2005; 65:3998-4004.
10. Min/+ mice. Neoplasia 2012; 14:159-168.
11. Oving IM, Clevers HC. Molecular causes of colon cancer. Eur J Clin Invest 2002; 32:448-457.
12. Kirchberger S, Royston DJ, Boulard O, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. JEM 2013; 210:917-931.
13. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. JEM 2005; 202:1075-1085.
14. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998.
15. Pietra G, Manzini C, Rivara S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72:1407-1415.
16. Sutmuller RP, van Duivenvoordea LM, van Elsasa A. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-832.
17. Needham DJ, Lee JX, Beilharz MW. Intra-tumoural regulatory T cells: A potential new target in cancer immunotherapy. Biochem Biophys Res Commun 2006; 343:684-691.
18. Clarke SL, Betts GJ, Plant A, et al. CD4+ CD25+ FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 2006; 1:e129.
19. Bonertz A, Weitz J, Pietsch D-HK, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311-3321.
20. Erdman SE, Rao VP, Poutahidis T, et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 2003; 63:6042-6050.
21. Grauer OM, Nierkens S, Bennink E, et al. CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121:95-105.
22. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176:1582-1587.
23. Morandi B, Mortara L, Chiossone L, et al. Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS ONE 2012; 7:e39170.
24. Martin J, Bossard C, Boureille A, Josien R. Differential regulation of IL-22BP in Crohn's disease versus ulcerative colitis. J Transl Med 2011; 9:11.
25. Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012; 491:259-263.
26. Martin JCJ, Bériou G, Heslan M, et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol advance online publication. 2014; 7:101-113.
27. Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-1111.
28. Ma X, Wang S, Ye Y, Du RY, Cui ZR, Somsouk M. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 2004; 10:1569-1573.
29. Bedel R, Thiery-Vuillemin A, Grandclement C, et al. Novel Role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res 2011; 71:1615-1626.
30. Di Virgilio F, Ferrari D, Adinolfi E. P2X7: A growth-promoting receptor-implications for cancer. Purinergic Signal 2009; 5:251-256.